Ad is loading...
NVCR
Price
$17.09
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
90 days until earnings call
XWEL
Price
$1.45
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

NVCR vs XWEL

Header iconNVCR vs XWEL Comparison
Open Charts NVCR vs XWELBanner chart's image
NovoCure
Price$17.09
Change-$0.00 (-0.00%)
Volume$809.72K
CapitalizationN/A
XWELL
Price$1.45
Change-$0.00 (-0.00%)
Volume$14.33K
CapitalizationN/A
NVCR vs XWEL Comparison Chart
Loading...
NVCR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XWEL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NVCR vs. XWEL commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVCR is a Hold and XWEL is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (NVCR: $17.73 vs. XWEL: $1.50)
Brand notoriety: NVCR and XWEL are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: NVCR: 65% vs. XWEL: 269%
Market capitalization -- NVCR: $1.66B vs. XWEL: $7.06M
NVCR [@Medical Specialties] is valued at $1.66B. XWEL’s [@Medical Specialties] market capitalization is $7.06M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVCR’s FA Score shows that 1 FA rating(s) are green whileXWEL’s FA Score has 1 green FA rating(s).

  • NVCR’s FA Score: 1 green, 4 red.
  • XWEL’s FA Score: 1 green, 4 red.
According to our system of comparison, both NVCR and XWEL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVCR’s TA Score shows that 4 TA indicator(s) are bullish while XWEL’s TA Score has 4 bullish TA indicator(s).

  • NVCR’s TA Score: 4 bullish, 6 bearish.
  • XWEL’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, NVCR is a better buy in the short-term than XWEL.

Price Growth

NVCR (@Medical Specialties) experienced а +10.06% price change this week, while XWEL (@Medical Specialties) price change was -9.35% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.02%. For the same industry, the average monthly price growth was +0.79%, and the average quarterly price growth was -2.06%.

Reported Earning Dates

NVCR is expected to report earnings on Feb 20, 2025.

XWEL is expected to report earnings on Nov 15, 2023.

Industries' Descriptions

@Medical Specialties (+3.02% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVCR($1.66B) has a higher market cap than XWEL($7.06M). NVCR YTD gains are higher at: 14.468 vs. XWEL (-16.862). XWEL has higher annual earnings (EBITDA): -17.82M vs. NVCR (-177.45M). NVCR has more cash in the bank: 911M vs. XWEL (26.1M). XWEL has less debt than NVCR: XWEL (11.5M) vs NVCR (596M). NVCR has higher revenues than XWEL: NVCR (509M) vs XWEL (30.3M).
NVCRXWELNVCR / XWEL
Capitalization1.66B7.06M23,485%
EBITDA-177.45M-17.82M996%
Gain YTD14.468-16.862-86%
P/E RatioN/AN/A-
Revenue509M30.3M1,680%
Total Cash911M26.1M3,490%
Total Debt596M11.5M5,183%
FUNDAMENTALS RATINGS
NVCR vs XWEL: Fundamental Ratings
NVCR
XWEL
OUTLOOK RATING
1..100
8052
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5481
P/E GROWTH RATING
1..100
121
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XWEL's Valuation (61) in the Other Consumer Services industry is somewhat better than the same rating for NVCR (100) in the Medical Specialties industry. This means that XWEL’s stock grew somewhat faster than NVCR’s over the last 12 months.

XWEL's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as NVCR (100) in the Medical Specialties industry. This means that XWEL’s stock grew similarly to NVCR’s over the last 12 months.

NVCR's SMR Rating (97) in the Medical Specialties industry is in the same range as XWEL (98) in the Other Consumer Services industry. This means that NVCR’s stock grew similarly to XWEL’s over the last 12 months.

NVCR's Price Growth Rating (54) in the Medical Specialties industry is in the same range as XWEL (81) in the Other Consumer Services industry. This means that NVCR’s stock grew similarly to XWEL’s over the last 12 months.

XWEL's P/E Growth Rating (1) in the Other Consumer Services industry is in the same range as NVCR (12) in the Medical Specialties industry. This means that XWEL’s stock grew similarly to NVCR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVCRXWEL
RSI
ODDS (%)
Bearish Trend 5 days ago
83%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 18 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
NVCR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XWEL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GXAI1.280.05
+4.07%
Gaxosai
CDP31.160.47
+1.53%
COPT Defense Properties
MERC6.360.08
+1.27%
Mercer International
GMAB20.470.02
+0.10%
Genmab A/S ADS
TELA2.89-0.01
-0.34%
TELA Bio

NVCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with KIDS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then KIDS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVCR
1D Price
Change %
NVCR100%
+1.36%
KIDS - NVCR
43%
Loosely correlated
+3.80%
GH - NVCR
43%
Loosely correlated
+0.98%
VCYT - NVCR
43%
Loosely correlated
-0.66%
TWST - NVCR
43%
Loosely correlated
+1.34%
MASS - NVCR
42%
Loosely correlated
+7.03%
More

XWEL and

Correlation & Price change

A.I.dvisor tells us that XWEL and DRIO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XWEL and DRIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XWEL
1D Price
Change %
XWEL100%
-2.91%
DRIO - XWEL
28%
Poorly correlated
+6.40%
COCH - XWEL
25%
Poorly correlated
+2.33%
XRAY - XWEL
23%
Poorly correlated
+0.65%
NVCR - XWEL
22%
Poorly correlated
+1.36%
CHEK - XWEL
21%
Poorly correlated
+6.37%
More